Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand

AstraZeneca4,108 enrolled

Overview

This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Study Type

OBSERVATIONAL

Enrollment

4,108

Conditions

Upper GIT Symptoms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Female or male aged at least 18 years * Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation Exclusion Criteria: * Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site * Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months

Locations (25)

Research Site

Bangkok Noi, Bangkok, Thailand

Research Site

Muang, Bangkok, Thailand

Outcomes

Primary Outcomes

Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms

Secondary Outcomes

Response to various treatments for patients who have been diagnosed of GERD

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.